Virus Purification with Membrane Chromatography



Similar documents
Process-scale purification of monoclonal antibodies polishing using Capto Q

Monoclonal antibodies

Monoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.

Application Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary

Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform

Application Note. Separation of three monoclonal antibody variants using MCSGP. Summary

Affi-Prep Protein A Matrix Instruction Manual

Bringing Downstream Productivity into Phase with Upstream Antibody Production

Advances in Biopharmaceutical and Vaccine Manufacturing Plants

Recent advances in the purification of IgM monoclonal antibodies

From Research Services and Process Development to GMP Manufacturing

A new, integrated, continuous purification process template for monoclonal antibodies

The Importance of Developing a High Yield of Product

Mustang Q XT Chromatography Capsules

The market for therapeutic monoclonal antibodies

50 g 650 L. *Average yields will vary depending upon a number of factors including type of phage, growth conditions used and developmental stage.

TECHNICAL BULLETIN. HIS-Select Nickel Affinity Gel. Catalog Number P6611 Storage Temperature 2 8 C

Vaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010

POROS CaptureSelect affinity columns for highspeed quantification of IgG Fc fusion proteins

RESOURCE Q, 1 ml and 6 ml RESOURCE S, 1 ml and 6 ml

Application Note. Increasing the activity of monoclonal antibody isoforms by MCSGP. Summary

Biopharmaceutical Process Evaluated for Viral Clearance

Manufacturing process of biologics

Genomic DNA Extraction Kit INSTRUCTION MANUAL

Data File. Sephadex G-25 media and pre-packed columns. Introduction. Sephadex G-25 Bead structure. Desalting/buffer exchange and gel filtration

Efficient Multi-Well Protein Purification Strategies

Customer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical

Expression and Purification of Recombinant Protein in bacteria and Yeast. Presented By: Puspa pandey, Mohit sachdeva & Ming yu

HiPer Ion Exchange Chromatography Teaching Kit

Bioprocessing Media and Buffers Grow with Us

KMS-Specialist & Customized Biosimilar Service

Manufacturing processes for

Method Development for Size-Exclusion Chromatography of Monoclonal Antibodies and Higher Order Aggregates

Guide to Reverse Phase SpinColumns Chromatography for Sample Prep

A novel AIEX chromatography medium (resin) to remove IgA and IVIG purification process

Guidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing

3 Chapter Three: Material and methods (clone creation, upstream and downstream process)

Aurum Ion Exchange Mini Kits and Columns. Instruction Manual

Protein Purification Handbook

High-throughput Process Development with PreDictor Plates

Accelerating drug development to FTIH: Potential of new expression technologies

Trends in Upstream and Downstream Process Development for Antibody Manufacturing

UltraClean PCR Clean-Up Kit

HiTrap Heparin HP, 1 ml and 5 ml

His GraviTrap. GE Healthcare. Operation

Introduction to Bioprocessing

MagExtractor -Genome-

Continuous Chromatography for Monoclonal Antibody Purification from Cell Culture Supernatant

Rubisco; easy Purification and Immunochemical Determination

Production of proteins for medical use in TG silkworms

Chromatographic Methods for the Purification of Monoclonal Antibodies and their Alternatives:A Review

Interim Progress Report R&D Project 348. Development of a Field Test Kit for Detection of Blue-Green Algal Toxins

Viral Safety of Plasma-Derived Products

Marmara Üniversitesi Fen-Edebiyat Fakültesi Kimya Bölümü / Biyokimya Anabilim Dalı PURIFICATION AND CHARACTERIZATION OF PROTEINS

Hydrophobic Interaction Chromatography

Application Note. Determination of Nitrite and Nitrate in Fruit Juices by UV Detection. Summary. Introduction. Experimental Sample Preparation

Size Exclusion Chromatography

UltraClean Soil DNA Isolation Kit

TIANquick Mini Purification Kit

Classic Immunoprecipitation

Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography

Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies

How To Test For Cleaning Efficiency With A Predictor 96 Well Filter Plate

Risk analysis and management is the cornerstone

THOMAS C. RANSOHOFF Vice President and Principal Consultant

Choose your optimal tools for protein studies

During regulatory inspections,

Transgenic technology in the production of therapeutic proteins

Multiple Products in a Monoclonal Antibody S88.01 Batch Plant

Luca Romagnoli, Ph.D. Business Development Manager

Overview of Upstream and Downstream Processing of Biopharmaceuticals

Covalent Conjugation to Cytodiagnostics Carboxylated Gold Nanoparticles Tech Note #105

Fast, easy and effective transfection reagent for mammalian cells

Chapter 18: Applications of Immunology

Size Exclusion Chromatography

TransIT Transfection Reagent

Bio-manufacturing of antigens, antibodies and bioresearch materials

QuickTiter Hepatitis B Surface Antigen (HBsAg) ELISA Kit

Biomanufacturing Vision for the Future

Robert Birdsall, Eoin Cosgrave, Henry Shion, and Weibin Chen Waters Corporation, Milford, MA, USA APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS

Evaluation of an alkali stable Protein A matrix versus Protein A Sepharose Fast Flow and considerations on process scale-up to 20,000L.

Recombinant protein vaccines produced in insect cells

Peptide synthesis, radiolabelling and radiochemical analysis

PowerFecal DNA Isolation Kit

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

QuickTiter FeLV Core Antigen ELISA Kit (FeLV p27)

GRS Plasmid Purification Kit Transfection Grade GK (2 MaxiPreps)

PureLink HiPure Plasmid Filter Purification Kits

LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals

VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN Q5A(R1)

GE Healthcare. Hydrophobic Interaction and Reversed Phase Chromatography. Principles and Methods

Optimal Conditions for F(ab ) 2 Antibody Fragment Production from Mouse IgG2a

Gain efficiency in your process development with ÄKTA avant

AxyPrep Blood Genomic DNA Maxiprep Kit

In Vitro And In Vivo Production Of Antibodies

SCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production

Manual for: sirna-trans Maximo Reagent

Valentina Gualato, Ph.D. Process Development Scientist

High-Throughput 3-D Chromatography Through Ion Exchange SPE

Transcription:

Virus Purification with Membrane Chromatography 1 st Workshop European Network of Viral Vaccines Processes, October 14-15, 2010, Frankfurt am Main Stefan Fischer-Frühholz, Laura Chirica, Miyako Hirai, Rene Faber, Uwe Gottschalk Sartorius Stedim Biotech GmbH

Agenda 1. Outline single use Membranes 2. Virus removal 3. Virus purification Page 2

Diffusion limited gels versus convective limited membranes (high flow rate) Average pore size 15-40 nm Average pore size 3-5 μm Page 3

Mainly ion exchangers for removal & purification of viruses 4 mm bed 8 mm bed Q S STIC Q S HIC nano 1 ml mini 5 10 20 30 mega nano 3 ml 150 ml Jumbo 5 l Contaminant removal: flowthrough mode to remove DNA, Host cell proteins, endotoxins, viruses Singe-use Purification: bind & elute of viruses and virus like particles, large proteins Single-use / intra-batch use Page 4

Membrane Adsorbers - highest growth of single-use solutions Page 5

15 reasons why single-use: Product faster to market Reduction of complexity Reduce space No cleaning validation Decrease product contamination More flexible Simplify operations Reduce hazardous cleaning solutions More convenient Increase facility output Assure sterility Reduce water and buffer consumption Lower maintanance cost Reduce time to get facility running Faster optimization Page 6

Further acceptance for single-use / intra batch reuse implies: Standardizaton of validation requirements Technology innovation & integration Scalable ranges & proof of scalability High volume, high flow systems from 2 to 2,000 L Product quality, robustness and integrity Delivery reliability & security of supply Cost improvements Page 7

Agenda 1. Outline singe use membranes 2. Virus removal 3. Virus purification Page 8

Virus removal study - polishing after CIEX column Virus Enveloped LRV Run 1 LRV Run 2 Virus recovery (%) MVM: Minute Virus of Mice no 6.03 ± 0.21 6.03 ± 0.20 100 Reo-3: Reovirus Type III no 7.00 ± 0.31 6.94 ± 0.24 100 MuLV*: Murine Leukemia Virus yes 5.35 ± 0.23 5.52 ± 0.27 > 70 PRV: Pseudorabies virus yes 5.58 ± 0.28 5.58 ± 0.22 100 ph: 7.2, conductivity: 4 ms/cm, flow rate: 450 cm/h, 1 % spike protein concentration: 4.3 g/l Mab load: 10.9 kg/l membrane (3 kg/m²) *LRV = 5.59 at 600 cm/hr Zhou J and Tressel T: Basic Concepts in Q Membrane Chromatography for Large-Scale Antibody Production. Biotechnol Prog., 22 (2) 341 349, 2006 Page 9

Salt tolerant anion exchanger Sartobind STIC (-NH 2 ligand) Protein Binding [g/l] Sartobind Q BSA in 200 mm NaCl (20 ms/cm) 3.6 36 DNA Binding [g/l] DNA in 50 mm NaCl (7 ms/cm) 7.3 22 LRV with Mouse Minute Virus (MMV) Fraction 1, 150 mm NaCl Fraction 2, 150 mm NaCl 2.10 1.81 Sartobind STIC 3.82 > 4.96 Sartobind STIC PA (primary amine) - provides higher binding capacity compared to Q anion exchanger at higher conductivity - enables the polishing at broader operating conditions (high salt) Page 10

Phosphate and other multivalent anions inhibit the binding of ΦX174 (virus surrogate) Load 4*10 7 pfu/ml ΦX174, LP15, flow rate 20ml/min LRV 5 4,5 4 3,5 3 2,5 2 1,5 Sartobind Q Sartobind STIC 1 0,5 0 Buffer 25mM TRIS/HCl 25mM TRIS/HCl 25mM TRIS/HCl 25mM TRIS/HCl 20mM KPi 20mM KPi 20mM KPi 20mM KPi ph NaCl [mm] 7,5 7,5 8 8 7,5 7,5 8 8 0 150 0 150 0 150 0 150 Page 11

Phosphate inhibits phage binding but DNA contaminant is bound Sartobind STIC to be used at binding conditions of viruses Ortho phosphate mm Phage in flowthrough % of start material 0 <0.00001 <1 2 <0.0001 <1 10 0.001 <1 30 75-83 <1 DNA in flowthrough % of start material 15 cm² (3 layers) Sartobind STIC PA were loaded with 150 ml ΦX174 1 x 10 7 PFU/ml, salmon sperm DNA 200 ng/ml at 10 ml/min was added. Page 12

Agenda 1. Outline single use membranes 2. Virus removal 3. Virus purification Page 13

Virus capture / purification Single-use / intra batch reuse Influenza virus 2,3 Adenovirus 4,5,6 Lentivirus 7 Adenoassociated virus Baculovirus 8 Densonucleosis virus 9 Pseudorabies virus 10 Bovine herpesvirus 1 Foot and mouth desease virus 11 Rotavirus like particles 12 Bacteriophages 13 Norovirus (VLP) 14 Page 14

Membrane Adsorbers vs. Density Gradient Membrane Adsorbers Density gradient ultra centrifugation 2 hours 36 hours Up to 10 13 VP/ml No carryover, disposable, no validation, simple No contaminants 10 6 VP/ml Carryover validation Toxic CsCl 2, sucrose removal from finished product Page 15

Purification of PRV Virions with S Cation Exchanger - The virulent wild type NIA3 strain of Pseudorabies virus as well as its GFP expressing derivative were grown by infecting confluent PK15 cell monolayers - After a 48 h growth period, the cell culture medium, containing progeny virions, was collected, chilled on ice and clarified by centrifugation at 4 C. - Virions were purified by ion exchange chromatography on Sartobind S cation exchanger membranes as described previously [45] except that SingleSep minicapsules were used Flori L et al., Transcriptomic analysis of the dialogue between Pseudorabies virus and porcine epithelial cells during infection. BMC Genomics 2008, 9:123 INRA, DGA, UMR 314, Laboratoire de Radiobiologie et d'etude du Génome, France [45] Karger A, Schmidt J, Mettenleiter TC: Infectivity of a pseudorabies virus mutant lacking attachment glycoproteins C and D. J Virol 1998, 72:7341-7348 Page 16

Purification of Baculoviruses with Anion Exchanger - Recombinant baculoviruses (rbvs) are widely used as vectors for the production of recombinant proteins in insect cells. - A complete downstream process comprising three steps was successfully developed: - depth filtration - ultra/ diafiltration - membrane adsorption (Sartobind D) - Global recovery yields reaching 40% (at purities over 98%) and, most importantly, relies on technologies easy to transfer to process scales under cgmp guidelines. Vicente T et al, Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Therapy (2009), 1 10 IBET/ITQB-UNL, Animal Cell Technology Laboratory, Portugal Page 17

Purification of Influenza Viruses with Q Anion Exchanger - Human and equine influenza A virus in cell culture supernatant (serum-free and serumcontaining cultivation) was directly adsorbed to Sartobind Q and D 75 anion-exchangers. - Elution of adsorbed virus from Sartobind Q by displacement with sodium chloride (up to 1.5 M, ph 7.0) resulted in average yields of 86% (based on HA activity). - Due to their high productivity, ease of operation and acceptable yields Sartobind Q anion-exchangers can be considered promising candidates for the large-scale purification of cell culture derived influenza virus. Kalbfuss B et al., Direct capture of influenza A virus from cell culture supernatant with Sartobind anion-exchange membrane adsorbers. Journal of Membrane Science 299 (2007) 251 260 Bioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, Germany Page 18

Purification of PPV Virus Spike PDA Technical Report No. 47: Preparation of virus Spikes used for Virus Clearance Studies 2010, p19-20 Page 19

Current applications for vaccines Capture Influenza vaccine Rabies vaccine Adenovirus-vectored vaccine Polio vaccine Conjugated vaccine VLP Polishing DNA removal HCP removal Page 20

Summary Membrane chromatography is established in polishing applications Tool for virus removal in biopharmaceutical production as single-use solution Many applications for virus capture first uses in the vaccine industry Driving force for using membrane chromatography: productivity and ease of use. Page 21

References 1. Karger A, Schmidt J, Mettenleiter TC. Infectivity of a pseudorabies virus mutant lacking attachment glycoproteins C and D. J Virol 1998, 72, 7341-7348 2. Kalbfuss B, Wolff M, Geisler L, Tappe A, Wickramasinghe R, Thom V, Reichl U. Direct capture of influenza A virus from cell culture supernatant with Sartobind anion-exange membrane absorbers. J. Membrane Sci 2007, 299, 251-260 3. Opitz L, Lehmann S, Reichl U, Wolff MW. Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles. Biotechnol Bioeng 2009,103(6), 1144-1154 4. Zeidler R, Fischer-Frühholz S. Schnelle und einfache Reinigung von Adenoviren. F&D LP, 2004, Sep, 28-29 5. Delmdahl N. Fast, effective and safe adenovirus purification with Vivapure AdenoPACK kits. Nature Methods 2006, Aug 6. Peixoto C, Ferreira TB, Sousa MF, Carrondo MJ, Alves PM. Towards purification of adenoviral vectors based on membrane technology. Biotechnol Prog 2008, 24(6), 1290-6 7. Vivapure Virus Purification and Concentration Kits. Brochure 85030-530-78, Sartorius Stedim GmbH 8. Vicente T, Peixoto C, Carrondo MJT, Alves PM. Purification of recombinant baculoviruses for gene therapy using membrane processes. Gene Therapy, 2009, 16, 766 775 9. Specht, R, Han, B, Wickramasinghe, SR, Carlson, JO, Czermak, P, Wolf, A, Reif, O-W. Densonucleosis virus purification by ion exchange membranes. Biotechnol Bioeng 2004, 88(4), 465-473 10. Karger A, Schmidt J, Mettenleiter TC. Infectivity of a pseudorabies virus mutant lacking attachment glycoproteins C and D. J Virol 1998, 72, 7341-7348 11. Oswald T. DSP in Vaccine manufacturing and development. Downstream Technology Forum, London, Nov. 2004 12. Vicente T, Sousa MFQ, Peixoto C, Mota JPB, Alves PM, Carrondo MJT. Anion-exchange membrane chromatography for purification of rotavirus-like particles. Journal of Membrane Science 311 2008 270 283 13. Sartorius Stedim Biotech Application Note Capture of Bacteriophage PR772. 85034-536-34, 2009 14. Taylor, R., Production and Downstream Processing of Norovirus Virus-Like Particles, Bio Process International conference, Providence, Rhode Island, 20-24 Sept. 2010 HCP removal: Ziegler T, Delvaille D. Contaminant removal in purification processes by membrane chromatography for recombinant proteins in early clinical development. American Pharmaceutical Review 2008 March/April DNA removal: Chen B, Glynn J. Development of a Positive-Charged Membrane Chromatography Step. ACS Meeting, Boston, 19-23 Aug. 2007 Endotoxin removal: Clutterbuck A, Kenworthy J, Liddell J. Endotoxin reduction using disposable membrane adsorption technology in cgmp manufacturing. BioPharm Int. May 2007 Page 22

Thank you! stefan.fischerf@sartorius-stedim.com www.sartorius-stedim.com Page 23